Drug Approvals
🇪🇺 EMAEMA news and analysis for pharmaceutical BD, investment, and market access
Track global drug approvals & regulatory decisions. Gain critical intelligence on new therapies, market access, and competitive landscapes for pharma BD.
Showing 1–12 of 197 articles
Quick answer
NovaPharmaNews Drug Approvals hub for EMA covers 197 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
EMA board backs Ebola response, flags 2025 annual report at June meeting
FDA approves capivasertib plus abiraterone and prednisone in PTEN-deficient mHSPC
Novo wins UK approval as race to launch weight-loss pill intensifies
Truqap gains US approval in PTEN-deficient metastatic prostate cancer
Duty of care at oncology conferences spotlights planetary health research
Synthetic real-world data reshapes oncology trial decision-making
AI in Drug Discovery Examples: What’s Changed Beyond Early Use Cases
EMA approved 104 human medicines in 2025: what changed
EMA Post Authorisation Guidance Faces Evidence Gaps After 10 Years
EMA approves TX01 PIP, unlocking the PUMA pathway for Theranexus and Exeltis
CHMP backs nerandomilast for IPF and PPF in EU
Eye drugs list: Sodium hyaluronate, tafluprost, tobramycin uses
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.